Silver Book Fact

It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%, in 2 years.  This means that 11,784 people would be spared blindness in that time period.

Bressler, Neil M., Quan V. Doan, Rohit Varma, Paul P. Lee, Ivan J. suner, Chantal Dolan, Mark D. Danese, Elaine Yu, Irwin Tran and Soshana Colman. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/427350

Reference

Title
Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration
Publication
Arch Ophthalmol
Publication Date
2011
Authors
Bressler, Neil M., Quan V. Doan, Rohit Varma, Paul P. Lee, Ivan J. suner, Chantal Dolan, Mark D. Danese, Elaine Yu, Irwin Tran and Soshana Colman
Volume & Issue
Volume 129, Issue 6
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Studies of patients with myocardial infarction found that warfarin reduced stroke risk compared to placeboby 40% to 55%.  
  • Screening and treatment for diabetic retinopathy in type 2 diabetes patients produces annual savings of 53,986 person-years of sight.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…